Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic versus locoregional injection of radiolabelled somatostatin analogues in GEP neuroendocrine tumors
2008-006889-29Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Oct 2008
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of indium-111 pentetreotide in Gastroenteropancreatic Carcinoid Tumor and Bronchopulmonary Carcinoid (BPC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Uptake of 111In-DTPA-octreotide in intrahepatic tumor metastasis. Started Oct 2008; status: active.
02
Drugs
indium-111 pentetreotide
03
Conditions
Gastroenteropancreatic Carcinoid TumorBronchopulmonary Carcinoid (BPC)
Beyond the preview
Go deeper on 2008-006889-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006889-29.